US Patent

US7674479 — Sustained-release bupropion and bupropion/mecamylamine tablets

Formulation · Assigned to IntelGenx Corp · Expires 2028-08-23 · 2y remaining

Vulnerability score 60/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method for making sustained-release tablets containing bupropion hydrochloride and optionally mecamylamine hydrochloride.

USPTO Abstract

Sustained-release bupropion hydrochloride pharmaceutical tablets and combination sustained-release bupropion hydrochloride/mecamylamine hydrochloride pharmaceutical tablets are obtained by granulating the bupropion hydrochloride with a hydroxyalkylcelluose, and blending the resulting granules within an extragranular phase composed of a particulate material that provides a sustained-release matrix, and compressing the blend into a tablet form, which then is coated, with a means to provide delayed release, such as with an enteric coating composition. The mecamylamine hydrochloride can be contained in a second granule comprising a hydroxyalkylcellulose.

Drugs covered by this patent

Patent Metadata

Patent number
US7674479
Jurisdiction
US
Classification
Formulation
Expires
2028-08-23
Drug substance claim
No
Drug product claim
Yes
Assignee
IntelGenx Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.